Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.06|
|52 Week High||AU$0.052|
|52 Week Low||AU$0.15|
|1 Month Change||-13.04%|
|3 Month Change||-10.45%|
|1 Year Change||-57.14%|
|3 Year Change||13.21%|
|5 Year Change||-50.00%|
|Change since IPO||-99.96%|
Recent News & Updates
Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Will Memphasys (ASX:MEM) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|MEM||AU Life Sciences||AU Market|
Return vs Industry: MEM underperformed the Australian Life Sciences industry which returned -2.7% over the past year.
Return vs Market: MEM underperformed the Australian Market which returned 20.3% over the past year.
Stable Share Price: MEM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MEM's weekly volatility (9%) has been stable over the past year.
About the Company
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016.
Memphasys Fundamentals Summary
|MEM fundamental statistics|
Is MEM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MEM income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0019|
|Net Profit Margin||0.00%|
How did MEM perform over the long term?See historical performance and comparison
Is Memphasys undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MEM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MEM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MEM is unprofitable, so we can't compare its PE Ratio to the Global Life Sciences industry average.
PE vs Market: MEM is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MEM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MEM is overvalued based on its PB Ratio (5.5x) compared to the AU Life Sciences industry average (5x).
How is Memphasys forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Memphasys has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Memphasys performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEM is currently unprofitable.
Growing Profit Margin: MEM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MEM is unprofitable, but has reduced losses over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare MEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MEM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (59.8%).
Return on Equity
High ROE: MEM has a negative Return on Equity (-17.27%), as it is currently unprofitable.
How is Memphasys's financial position?
Financial Position Analysis
Short Term Liabilities: MEM's short term assets (A$3.7M) exceed its short term liabilities (A$856.8K).
Long Term Liabilities: MEM's short term assets (A$3.7M) do not cover its long term liabilities (A$5.1M).
Debt to Equity History and Analysis
Debt Level: MEM's debt to equity ratio (38.9%) is considered satisfactory.
Reducing Debt: MEM's debt to equity ratio has reduced from 332.5% to 38.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MEM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MEM has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 7.2% each year
What is Memphasys's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MEM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MEM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MEM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MEM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MEM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Alison Mary Coutts, B.E (Chem), MBA, Grad Dip. Biotech, has been an Interim Chief Executive Officer of Memphasys Limited (formerly, NuSep Holdings Ltd) since February 10, 2014 and has been its Executiv...
CEO Compensation Analysis
Compensation vs Market: Alison's total compensation ($USD284.42K) is about average for companies of similar size in the Australian market ($USD301.95K).
Compensation vs Earnings: Alison's compensation has been consistent with company performance over the past year.
Experienced Management: MEM's management team is considered experienced (4.9 years average tenure).
Experienced Board: MEM's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.
Memphasys Limited's employee growth, exchange listings and data sources
- Name: Memphasys Limited
- Ticker: MEM
- Exchange: ASX
- Founded: 2006
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$48.323m
- Shares outstanding: 792.18m
- Website: https://www.memphasys.com
- Memphasys Limited
- 30 Richmond Road
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 07:03|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.